Guerbet SA (GBT.PA)

17.2 €

+0.40 (+2.38%)
Rating:
Recommendation:
-
Symbol GBT.PA
Price 17.2 €
Beta 0.807
Volume Avg. 0.02M
Market Cap 217.093M
Shares () -
52 Week Range 15.42-38.75
1y Target Est -
DCF Unlevered GBT.PA DCF ->
DCF Levered GBT.PA LDCF ->
ROE 10.01% Buy
ROA 3.95% Neutral
Operating Margin -
Debt / Equity 134.29% Buy
P/E 6.67 Buy
P/B 0.50 Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. David Hale
Healthcare
Medical Devices
Paris

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem, a gadoteric acid that acts as a contrast agent for MRI, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain, a cloud-based AI solution to quantify disease-specific brain structures for acute and chronic neurological conditions on MR and CT, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppyseed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, a blue dye; Axessio, a peripheral micro guidewire; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. The company was founded in 1926 and is headquartered in Villepinte, France.